PMVP
PMV Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.50
+2.74%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +13.2%
- EBIT
- +12.9%
- EPS
- -89.3%
- Free cash flow
- -1.6%
- Operating cash flow
- -1.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +67.9%
- EPS
- +19.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -8.3%
- EBIT
- -0.9%
- Net income
- -32.4%
- EPS
- -30.0%
- Free cash flow
- -41.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026